IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.78
−0.47%Aug 19, 2026, 10:00 UTC
IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.
Source:Aug 4, 2026, 10:00 UTC
IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.
Source:Jun 15, 2026, 10:00 UTC
IDEAYA Biosciences initiated a Phase 1/2 clinical combination study for its IDE892 MTA-Cooperative PRMT5 inhibitor in MTAP-deleted pancreatic and lung cancers.
Jun 10, 2026, 20:05 UTC
IDEAYA Biosciences closed an underwritten public offering of 7,222,225 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock.
Source:Jun 8, 2026, 20:01 UTC
IDEAYA Biosciences announced a proposed public offering of up to $300 million of common stock and pre-funded warrants.
Source:Jun 3, 2026, 10:00 UTC
IDEAYA Biosciences entered into a clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 for MTAP-deleted RAS-mutant pancreatic cancer.
Source: